Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several medical/label-consistent claims match the provided label excerpts (indication, dosing/administration route/site and once-daily use, osteosarcoma warning rationale, exclusion of certain skeletal radiation history, general concept of stimulating new bone formation). However, multiple claims are unsupported or only partially supported by the provided excerpts (e.g., “daily injection treats…,” “approved course lasts up to two years,” specific ‘common reactions’ such as leg cramps/nausea/dizziness, switching to antiresorptives after therapy, and several non-label facts about biosimilars/exclusivity).
Category Scores
Accurate Statements
Forteo contains teriparatide.
Label excerpt lists active ingredient as teriparatide (Drug/Active ingredient section and Mechanism/PD excerpts refer to teriparatide).
Forteo mimics parathyroid hormone.
Mechanism of Action excerpt: biological actions of PTH and teriparatide mediated through binding to specific receptors; once-daily administration stimulates new bone formation.
Forteo increases osteoblast activity.
No explicit mention of osteoblast activity in provided excerpts; however, Mechanism excerpt states teriparatide stimulates new bone formation. (Note: this statement is only partially grounded; see unsupported/omission items.)
Forteo is injected once daily under the skin of the thigh or abdomen after training from a healthcare provider.
Dosage/Administration excerpt: subcutaneous injection into thigh or abdominal region; once daily; administration initially under circumstances where patient can sit/lie down if orthostatic hypotension occurs. (Training from a healthcare provider is not explicitly in the provided excerpts.)
The end of regulatory exclusivity has ended.
No label support provided for regulatory/exclusivity statements.
Unsupported Statements
Forteo is a daily injection that treats osteoporosis in people at high risk of fracture.
Indications support treatment of osteoporosis in high-risk-for-fracture patients, and dosing supports once-daily injection, but the provided excerpt does not use the exact phrasing ‘daily injection’ as a standalone statement. Still generally consistent with label, but the exact statement is not directly supported as written.
Forteo works by stimulating new bone formation rather than simply slowing bone loss.
Mechanism excerpt states once-daily teriparatide stimulates new bone formation, but the contrast ‘rather than simply slowing bone loss’ is not stated in the provided label excerpts.
Forteo increases osteoblast activity.
The provided excerpts do not explicitly state osteoblast activity.
Forteo actively builds bone.
Mechanism excerpt supports stimulation of new bone formation; ‘actively builds bone’ is interpretive wording not directly stated.
Forteo is an option when patients have already broken bones or show very low bone density despite other treatments.
Indications describe high risk for fracture including history of osteoporotic fracture or multiple risk factors, and ‘failed or intolerant to other available osteoporosis therapy.’ The provided excerpts do not mention ‘very low bone density’ wording.
The approved course of Forteo lasts up to two years.
Dosage/Administration excerpt states use of FORTEO for more than 2 years during a patient's lifetime should only be considered if high fracture risk persists. It does not state an ‘approved course lasts up to two years’ as a firm limit for all patients.
After Forteo therapy, patients usually switch to an antiresorptive drug to maintain the new bone gained during therapy.
No provided label excerpt states post-therapy switching to antiresorptives ‘usually’ or at all.
A boxed warning notes an increased risk of osteosarcoma in rats given high doses for long periods.
The provided excerpts include osteosarcoma warnings (no explicit boxed warning text is provided). The specifics ‘rats’ and ‘high doses for long periods’ are not in the supplied label excerpts.
Forteo is not recommended for people who have had bone cancer.
Osteosarcoma warning excerpt says avoid in patients with bone metastases or a history of skeletal malignancies. It does not specifically mention ‘bone cancer’ nor explicitly use ‘not recommended’ language.
Forteo is not recommended for people who have had radiation to the skeleton.
Label excerpt says avoid FORTEO use in patients with prior external beam or implant radiation therapy involving the skeleton. The claim is consistent in meaning but uses ‘not recommended’ phrasing; provided excerpts support ‘avoid’ rather than ‘not recommended.’
Common reactions to Forteo include leg cramps.
Postmarketing excerpt mentions ‘Musculoskeletal: Muscle spasms of the leg or back,’ but it does not specifically list ‘leg cramps’ as a common reaction.
Common reactions to Forteo include nausea.
No provided excerpt lists nausea among adverse reactions.
Common reactions to Forteo include dizziness.
No provided excerpt lists dizziness among adverse reactions (orthostatic hypotension is mentioned, but ‘dizziness’ is not explicitly provided).
Forteo can be self-injected at home.
The provided excerpts describe subcutaneous administration and device discard timing; they do not explicitly state self-injection at home.
The Forteo pen comes pre-filled.
The provided excerpt includes ‘single-patient-use prefilled pen’ in the drug/dosage form section, but no explicit label administration phrasing about ‘pen comes pre-filled’ was included beyond that. (Generally consistent, but only weakly supported as written.)
Teva launched the first teriparatide biosimilar in the United States in 2020.
No label support provided; label excerpts are clinical/pharmacology and do not address biosimilar launch dates.
The original product’s regulatory exclusivity has ended.
No label support provided.
The end of regulatory exclusivity has led to wider availability of lower-cost versions of teriparatide.
No label support provided.
Contradictions
Important Omissions
Contraindications (hypersensitivity to teriparatide/excipients) are not mentioned in the AI claims provided.
Importance:
Moderate
Orthostatic hypotension administration instruction details (initial circumstances and timing/resolution) are not conveyed.
Importance:
Moderate
Label-specific ‘avoid’ criteria for osteosarcoma risk (e.g., open epiphyses, Paget’s disease, hereditary disorders predisposing to osteosarcoma) are not covered.
Importance:
Moderate
Drug interaction information is not mentioned (digoxin risk via transient hypercalcemia).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The majority of safety-relevant claims are directionally consistent with the osteosarcoma ‘avoid’ warning, but several elements are unsupported or imprecise (boxed warning specifics; exclusions phrased as ‘not recommended’ vs ‘avoid’; adverse reaction ‘common reactions’ claims not supported; self-injection at home not supported). Regulatory/biosimilar claims are off-label/irrelevant to safety and could distract from label-based use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported by the provided label excerpts, especially adverse reactions (‘common reactions’), boxed warning specifics, duration wording, and post-therapy switching and self-injection assertions. Several regulatory/biosimilar statements have no label basis.
Suggested Improvement
Restrict statements to what the provided excerpts explicitly support: use of ‘avoid’ language for osteosarcoma risk groups, align treatment duration with ‘more than 2 years only if high fracture risk persists,’ avoid listing specific ‘common’ adverse reactions unless present in supplied excerpts, and remove/segregate non-label regulatory/biosimilar availability claims.